Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Annovis Bio, Inc. Common Stock (NY:ANVS)

1.990 +0.180 (+9.94%)
Streaming Delayed Price Updated: 10:30 AM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Annovis Bio, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Approval for New Form of Buntanetap
Via Investor Brand Network
Topics Intellectual Property
Costco To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
 
Via Benzinga
Peering Into Annovis Bio's Recent Short Interest
 
Via Benzinga
Why Did Annovis Bio (ANVS) Stock Close Up 80% Today?
ANVS stock closed up more than 75% today after Annovis announced encouraging clinical trial results for its Parkinson's drug, buntanetap. 
Via InvestorPlace
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Names Four New Members to Executive Team
Via Investor Brand Network
Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family 
Via Benzinga
Peering Into Annovis Bio's Recent Short Interest
 
Via Benzinga
What's Going On With Annovis Shares Today?
Annovis Bio shares rise in premarket trading on positive Phase III Parkinson's study results for buntanetap, showing cognitive improvements and stability compared to placebo. 
Via Benzinga
Tesla, Paramount Global, Annovis Bio, Eli Lilly, Amazon: Why These 5 Stocks Are On Investors' Radars Today
On Tuesday, the Dow Jones Industrial Average rose by 0.4%, closing at $39,331.85, while the S&P 500 also ended the day in positive territory. 
Via Benzinga
Topics Stocks
What's Going With Annovis Bio Shares Tuesday?
Annovis announced new data from its Phase III Parkinson's study. The study showed improvements on the Unified Parkinson's Disease Rating Scale following treatment with Buntanetap. 
Via Benzinga
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Releases Significant Findings from Phase 3 Parkinson’s Study, Schedules Webcast
Via Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Announces Results From Phase II/III Buntanetap Study for the Treatment of Alzheimer’s Disease
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Provisional Patent Covering Manufacturing Process of New Solid Forms of Buntanetap
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Submits Patent Application for New Composition of Buntanetap Matter
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Upcoming Investor Webcast Focused on PD, Lead Drug Candidate
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Officials to Present Results from Alzheimer’s Study at AAIC 2024
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Results of Recent Alzheimer’s Study, Schedules Investor Call
Via Investor Brand Network
Annovis Bio Inc. (NYSE: ANVS) Is ‘One to Watch’
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Event Spotlighting Lead Drug Candidate
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Annovis Announces New Publication in a Peer-Reviewed Journal
From Annovis Bio Inc.
Via GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
ANVS Stock Earnings: Annovis Bio Beats EPS for Q1 2024
ANVS stock results show that Annovis Bio beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
From Annovis Bio Inc.
Via GlobeNewswire
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
From Annovis Bio Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.